

### REMARKS

Claims 87, 92 and 123-132 were pending in the present application. Applicants have amended claims 87 and 126 and canceled claims 92 and 123-125 without prejudice. The amendment to claim 126 involves changing claim dependency and does not raise any issue of new matter. Support for the amendment to claim 87 can be found, *inter alia*, on page 2, lines 14-20 and in table 10 on page 26 of the original specification. Applicants contend that the present Supplemental Amendment is fully supported by the original specification and does not raise any issue of new matter. Therefore, entry of the present Supplemental Amendment is respectfully requested. Upon entry of the present Supplemental Amendment, claims 87 and 126-132 will be under examination.

Applicants also enclose a Rule 132 declaration from Dr. Jane Li stating that both the azithromycin monohydrate hemi-ethanol solvate and the azithromycin dihydrate keep their distinctive structural characteristics in the mixture of azithromycin monohydrate hemi-ethanol solvate and the azithromycin dehydrate.

CONCLUSION

In view of the claim amendments, the Rule 132 declaration and the remarks, further and favorable considerations of the presently pending claims are respectfully requested.

It is believed that no fee is required in connection with the present Amendment. However, if any fees are required, the Commissioner is authorized to charge such fees to our Deposit Account No. 16-1445.

Respectfully submitted,

Date: Aug 9, 2005      Lance Y. Liu

**Customer No. 28523**  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-1652

Lance Y. Liu  
Attorney for Applicant(s)  
Reg. No. 45,379